Početna stranicaDRREDDY • NSE
add
Dr Reddy's Laboratories Ltd
Preth. zaklj. cijena
1.195,35 ₹
Dnevni raspon
1.193,60 ₹ - 1.223,20 ₹
Godišnji raspon
1.074,00 ₹ - 1.421,49 ₹
Tržišna kapitalizacija
1,01 bil. INR
Prosječna količina
1,48 mil.
P/E omjer
18,96
Prinos dividende
0,66 %
Glavno tržište vrijednosnica
NSE
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(INR) | ruj 2024.info | Godišnja promjena |
---|---|---|
Prihod | 80,16 mlr. | 16,51 % |
Operativni troškovi | 29,72 mlr. | 24,54 % |
Neto dohodak | 12,55 mlr. | −15,18 % |
Neto profitabilnost | 15,66 | −27,20 % |
Zarada po dionici | 15,83 | −11,13 % |
EBITDA | 22,02 mlr. | 8,53 % |
Efektivna porezna stopa | 30,01 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(INR) | ruj 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 63,07 mlr. | −7,15 % |
Ukupna imovina | 465,96 mlr. | 34,27 % |
Ukupne obveze | 156,67 mlr. | 66,79 % |
Ukupni kapital | 309,28 mlr. | — |
Dionice u optjecaju | 833,05 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 3,26 | — |
Povrat imovine | 10,24 % | — |
Povrat kapitala | 13,21 % | — |
Tok novca
Neto promjena novca
(INR) | ruj 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | 12,55 mlr. | −15,18 % |
Gotovina od poslovanja | 9,32 mlr. | −48,03 % |
Gotovina iz ulaganja | −19,07 mlr. | −322,21 % |
Gotovina iz financiranja | 16,15 mlr. | 329,53 % |
Neto promjena novca | 6,37 mlr. | 1,03 % |
Slobodan tok novca | 3,92 mlr. | −72,47 % |
Više
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Glavni izvršni direktor
Osnovano
1984
Sjedište
Web-lokacija
Zaposlenici
27.048